Gynecological Cancer: Diagnosis and Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (21 June 2024) | Viewed by 3785

Special Issue Editor


E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Interests: clinical oncology; gynecological oncology; gyneco-oncology surgery; HPV
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The past decade was eventful in terms of diagnostic and therapeutic advances in the field of gynaecological cancer. In terms of surgical treatment, in cervical cancer, the rise and fall of minimally invasive surgery in early stages leaves the debate open, while in the cytoreductive surgery of ovarian cancer, the extended operations for complete tumour reduction became the standard of care, but patient selection for the latter operations is still an open issue. Targeted therapies have emerged in cervical, ovarian, and endometrial cancers in the past few years, becoming standards of care in international guidelines, with more and more information gained on the genetic background of these diseases. The deeper understanding of the molecular level of these tumours started a breakthrough in the diagnostic, prognostic, and therapeutic approaches. There is emerging data on the role of the microbiome in the pathogenesis of these tumours. In addition to prognostic factors, with the increasing number of cancer survivors, the questions of the quality of life, vaginal health, and sexual functions come into focus as well.

The topics of this Special Issue should focus on, but are not limited to, the following:

  • New biomarkers of screening and early detection in gynaecological cancers;
  • New biomarker-driven targeted treatment in gynaecological malignancies;
  • Preoperative assessment of gynaecological cancers;
  • Predictive value of biomarkers in the medical or surgical treatment of gynaecological cancers;
  • Surgical treatment of gynaecological cancers;
  • Immune environment and progress in immunotherapy of gynaecological cancers;
  • The role of the microbiome in gynaecological cancers;
  • Prognostic and therapeutic relevance of DNA repair defects;
  • Investigating the determinants of health-related quality of life in patients with gynaecological cancer;
  • Investigating and maintaining vaginal health and sexual functions in gynaecological cancer;
  • Gynaecological cancer and thrombosis.

Submissions of original preclinical or clinical papers contributing to the advances in this field, as well as reviews, are encouraged.

Dr. Zoard T. Krasznai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • ovarian cancer
  • cervical cancer
  • endometrial cancer
  • immunotherapy
  • targeted therapy
  • survival analysis
  • quality of life
  • screening
  • early detection
  • treatment
  • surgery
  • microbiome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

17 pages, 570 KiB  
Review
CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
by Clare Cutri-French, Dimitrios Nasioudis, Erin George and Janos L. Tanyi
Diagnostics 2024, 14(8), 819; https://doi.org/10.3390/diagnostics14080819 - 16 Apr 2024
Cited by 4 | Viewed by 2425
Abstract
The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier [...] Read more.
The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier in their implementation, several early phase clinical trials are currently evaluating CAR-T cell therapies targeting mesothelin, folate receptor a, HER2, MUC16, and B7H3. Ongoing challenges include cytokine-associated and “on-target, off-tumor” toxicities, while most common adverse events include cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation-like syndrome (HLH/MAS), and neurotoxicity. In the present review, we summarize the current status of CAR-T therapy in ovarian cancer and discuss future directions. Full article
(This article belongs to the Special Issue Gynecological Cancer: Diagnosis and Management)
Show Figures

Figure 1

Other

Jump to: Review

7 pages, 3427 KiB  
Interesting Images
Collision Tumor of the Ovary: Adult Granulosa Cell Tumor and Mesonephric-like Adenocarcinoma
by Yujin Lee, Mohammad Rizwan Alam, Jin-Hwi Kim, Chan Joo Kim, Su Lim Lee and Kwangil Yim
Diagnostics 2024, 14(13), 1412; https://doi.org/10.3390/diagnostics14131412 - 2 Jul 2024
Viewed by 896
Abstract
Collision tumors of the ovaries are rare, with only a few reports in the literature. Adult granulosa cell tumors are a relatively common primary tumor component of previously reported collision tumors. The combination of serous and mucinous tumors with adult granulosa cell tumors [...] Read more.
Collision tumors of the ovaries are rare, with only a few reports in the literature. Adult granulosa cell tumors are a relatively common primary tumor component of previously reported collision tumors. The combination of serous and mucinous tumors with adult granulosa cell tumors has been reported in several cases. On the other hand, mesonephric-like adenocarcinomas are rare neoplasms that commonly arise in the uterine corpus and ovaries. In this report, we present the case of a collision tumor composed of an adult granulosa cell tumor and mesonephric-like adenocarcinoma of the ovary in a 63-year-old woman. The initial magnetic resonance imaging findings showed a cystic mass with an internal hemorrhage, which suggested an adult granulosa cell tumor, and a solid mass with different enhancements. Microscopically, the tumor had two distinct components: An adult granulosa cell tumor and a mesonephric-like adenocarcinoma. Recognizing collision tumors consisting of slow-growing and aggressive tumors may prove beneficial in future diagnostic and treatment strategies. Full article
(This article belongs to the Special Issue Gynecological Cancer: Diagnosis and Management)
Show Figures

Figure 1

Back to TopTop